Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
- Status
- RECRUITING
- Phase
- PHASE1
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Status
- RECRUITING
- Phase
- PHASE3
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
- Status
- RECRUITING
- Phase
- PHASE2
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
- Status
- RECRUITING
- Phase
- PHASE3
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2